<DOC>
	<DOCNO>NCT00078910</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , exisulind , work different way stop tumor cell divide stop grow die . Giving chemotherapy drug surgery may shrink tumor remove . PURPOSE : This phase II trial study well neoadjuvant exisulind work treat patient undergo radical prostatectomy stage II stage III prostate cancer .</brief_summary>
	<brief_title>Neoadjuvant Exisulind Treating Patients Who Are Undergoing Radical Prostatectomy Stage II Stage III Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare effect neoadjuvant exisulind v neoadjuvant treatment apoptosis patient stage II III prostate cancer undergo radical prostatectomy . Secondary - Determine effect drug ( preoperatively ) surrogate endpoint biomarkers ( i.e. , prostate-specific antigen , high-grade prostatic intraepithelial neoplasia , MIB-1 , DNA ploidy ) patient . OUTLINE : This nonrandomized , control study . Patients assign 1 2 group base treat physician . - Control group : Patients undergo radical prostatectomy . - Treatment group : Patients receive oral exisulind daily 4 week . Patients undergo radical prostatectomy . Patients follow 1 month . PROJECTED ACCRUAL : A total 130 patient ( 65 per group ) accrue study within approximately 10-12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sulindac sulfone</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Clinical stage T1c3b , N0X , M0 Gleason score â‰¥ 6 Planning undergo pelvic lymphadenectomy radical prostatectomy Mayo Clinic Rochester Interval biopsy prostatectomy least 4 , 14 , week Selected patient Dr. R. P. Myers undergo prostatectomy enrollment period assign control group* NOTE : *Additional historical control may select Dr. Myers ' patient underwent prostatectomy within past 4 year PATIENT CHARACTERISTICS : Age 40 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Not specify Hepatic ALT normal ( 1045 U/L ) AST normal ( 1231 U/L ) Alkaline phosphatase normal ( 119309 U/L ) Bilirubin normal ( 0.11.0 mg/dL ) No history hepatitis , cirrhosis , hepatic dysfunction Renal Creatinine &lt; 1.5 mg/dL Other Fertile patient must use effective contraception No hypersensitivity sulindac ( treatment group ) PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy No concurrent chemotherapy Endocrine therapy No prior ablation ( treatment group ) No prior hormone replacement antiandrogen therapy ( e.g. , testosterone , diethylstilbestrol , leuprolide , goserelin , flutamide , bicalutamide , finasteride , nilutamide , megestrol ) No concurrent antiandrogen therapy , luteinizing hormonereleasing hormone agonist , finasteride , diethylstilbestrol Radiotherapy No prior pelvic radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics Other No prior treatment prostate cancer prostatectomy ( control group ) No concurrent cyclooxygenase2 inhibitor No concurrent sulindac No concurrent nonsteroidal antiinflammatory drug except lowdose ( 325 mg/day ) aspirin cardiovascular prophylaxis</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>